Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial

Zeymer, Uwe; Leiva, Orly; Hohnloser, Stefan; Steg, Philippe; Oldgren, Jonas; Nickenig, Georg; Kiss, Robert; Ongen, Zeki; Estrada, Jose; Ophuis, Ton; Lip, Gregory; Nordaby, Matias; Miede, Corinna; ten Berg, Jurrien; Bhatt, Deepak; Cannon, Christopher

doi:10.4244/eij-d-20-00799

Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial

Zeymer U., Leiva O., Hohnloser S. H., Steg P. G., Oldgren J., Nickenig G., ...Daha Fazla

EUROINTERVENTION, cilt.17, sa.6, ss.474-483, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 6
Basım Tarihi: 2021
Doi Numarası: 10.4244/eij-d-20-00799
Dergi Adı: EUROINTERVENTION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, MEDLINE
Sayfa Sayıları: ss.474-483
Anahtar Kelimeler: antithrombotic treatment, atrial fibrillation, bleeding, clinical trials, STEMI, stroke, WARFARIN, ANTICOAGULATION, ANGIOGRAPHY, STRATEGIES
İstanbul Üniversitesi Adresli: Evet

Özet

Background: Little is known about the optimal antithrombotic therapy in patients with atrial fibrillation undergoing PCI for ST-elevation myocardial infarction (STEMI).